Showing 1 - 8 results of 8 for search 'Yi-Long Wu', query time: 0.02s Refine Results
  1. 1
    Acquired DNA damage repairs deficiency-driven immune evolution and involved immune factors of local versus distant metastases in non-small cell lung cancer

    Acquired DNA damage repairs deficiency-driven immune evolution and involved immune factors of local versus distant metastases in non-small cell lung cancer by Wen-Fang Tang, Xiao-Jun Fan, Hua Bao, Rui Fu, Yi Liang, Min Wu, Chao Zhang, Jian Su, Yi-Long Wu, Wen-Zhao Zhong

    Published 2023-12-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer

    Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer by Li Liu, Qing Zhou, Xue Wu, Yang W Shao, Yi-Long Wu, Xiao-Xiao Peng, Shu-Yu Wu, Can Pi, Zhi-Hong Chen, Xu-Chao Zhang, Cun-Yi Gao, Ruoying Yu

    Published 2020-05-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma

    Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma by Lei Yang, Qing Zhou, Bo Zhang, Yi-Long Wu, Zhi-Hong Chen, Wen-zhao Zhong, Fen Wang, Yun-Ting He, Song Dong, Xue-Wu Wei, Wei-Dong Chen, Xiao-Rong Yang, Xue-Meng Shang

    Published 2022-02-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study

    Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study by Jian Wang, Yi-Long Wu, Xue Bai, De-Hua Wu, Si-Cong Ma, Xin-Ran Tang, Shuai Kang, Qiang John Fu, Chuan-Hui Cao, He-San Luo, Yu-Han Chen, Hong-Bo Zhu, Hong-Hong Yan, Zhong-Yi Dong

    Published 2020-05-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study

    Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study by Lin Shen, Qing Zhou, Ting Sun, Jie Wang, Hongming Pan, Yi-Long Wu, Jun Zhao, Jun Guo, Qingyuan Zhang, Ying Yuan, Yuxian Bai, Tianshu Liu, Yongqian Shu, Siyang Wang, Aiping Zhou, Dingwei Ye, Yujuan Gao, Silu Yang, Zuobai Wang

    Published 2020-05-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)

    A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001) by Hua-Jun Chen, Hai-Yan Tu, Yanping Hu, Yun Fan, Guowu Wu, Shundong Cang, Yi Yang, Nong Yang, Rui Ma, Gaowa Jin, Ximing Xu, Anwen Liu, Shubin Tang, Ying Cheng, Yan Yu, Chong-Rui Xu, Qing Zhou, Yi-Long Wu

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Redoxhigh phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinoma

    Redoxhigh phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinom... by Xue-Wu Wei, Chang Lu, Yi-Chen Zhang, Xue Fan, Chong-Rui Xu, Zhi-Hong Chen, Fen Wang, Xiao-Rong Yang, Jia-Yi Deng, Ming-Yi Yang, Qing Gou, Shi-Qi Mei, Wei-Chi Luo, Ri-Wei Zhong, Wen-Zhao Zhong, Jin-Ji Yang, Xu-Chao Zhang, Hai-Yan Tu, Yi-Long Wu, Qing Zhou

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Monitoring of Circulating Tumor DNA and Indication of De-Escalation Adjuvant Targeted Therapy for EGFR-Mutated NSCLC After Complete Resection

    Monitoring of Circulating Tumor DNA and Indication of De-Escalation Adjuvant Targeted Therapy for EGFR-Mutated NSCLC After Complete Resection by Song Dong, PhD, Bingfa Yan, PhD, Si-Yang Liu, PhD, Xuan Gao, PhD, Hui-Zhao Hong, MD, Hong-Ji Li, MD, Wei Gao, PhD, Hong-Hong Yan, PhD, Si-Yang Maggie Liu, PhD, Hai-Yan Tu, PhD, Yi Pan, PhD, Qing Zhou, PhD, Xue-Ning Yang, PhD, Xue-Feng Xia, PhD, Xin Yi, PhD, Wen-Zhao Zhong, PhD, Yi-Long Wu, MD, Jia-Tao Zhang, PhD

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: